Dupilumab, which binds the alpha subunit of IL-4 receptors (IL-4Rα type 1 and type 2), thus inhibiting the signaling of IL-4 and IL-13 acting on the IL-4 and IL-13 receptors, can block type 2 inflammation, leading to a significant improvement of both nasal polyps and other T2-related comorbidities. The gene discussed is IL4; the disease is nasal cavity polyp.